CTA |
|
Vaxjo ID |
213 |
|
Vaccine Adjuvant Name |
CTA |
|
Adjuvant VO ID |
VO_0005270
|
|
Description |
CTA is a genetic adjuvant that enhances the immunogenicity of DNA vaccines. Its mechanism involves ADP-ribosyltransferase activity and IL-6 dependence, with protein kinase A (PKA) being a key mediator in its signaling pathway. |
|
Stage of Development |
Research |
|
Components |
Cholera toxin (CT) and its subunits (A and B) have been intensively investigated as adjuvants for protein-based vaccines. |
|
Structure |
The paper describes fusing the CTA gene to other immunogen genes (e.g., HIV-1-derived Tat-Rev-Vif-Integrase-Nef fusion gene or OVA gene). It also mentions an ADP-ribosyltransferase catalytic center. |
|
Preparation |
Preparation involved fusing the CTA gene to specific immunogen genes (HIV-1-derived Tat-Rev-Vif-Integrase-Nef fusion gene or OVA gene) and also using site-directed mutagenesis for specific experiments. |
|
Function |
By fusing the CTA gene to either the HIV-1-derived Tat-Rev-Vif-Integrase-Nef fusion gene or the OVA gene, our study showed that the fusion of CTA in these DNA vaccines had no cytotoxic effect in vitro and significantly improved both the quantity and quality of the elicited CD8(+) T cell responses. |
|
Safety |
The fusion of CTA in the DNA vaccines showed no cytotoxic effect in vitro. |
| Related Vaccine(s) |
|
| References |
Wan et al., 2014: Wan Y, Ren X, Ren Y, Wang J, Hu Z, Xie X, Xu J. As a genetic adjuvant, CTA improves the immunogenicity of DNA vaccines in an ADP-ribosyltransferase activity- and IL-6-dependent manner. Vaccine. 2014; 32(19); 2173-2180. [PubMed: 24631089].
|
